← brief for 2026-09-04 · Slowing decline

Use of fixed-ratio combination of basal insulin and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Asians with type 2 diabetes.

Key takeaways

This review looks at putting long-acting insulin and a GLP-1 drug into a single fixed-dose shot for people in Asia with type 2 diabetes. It notes that in past trials, people of Asian background developed chronic kidney disease more often than others, even when everyone got the same careful trial care. This is a summary of existing work, not a new trial, so there are no new results. It matters here because diabetes is the most common cause of kidney damage.

Who did this work

Kong AP · O CK · Lai S · Wang CY · Chan JC

Source

Article · PubMed, the drug frontier · 2026 Sep 4
https://pubmed.ncbi.nlm.nih.gov/42697752/